胸腔内注入尿激酶治疗脓胸的临床研究  

Clinical Study of Intrathoracic Injection of Urokinase in the Treatment of Empyema

作　　者：郭昌[1] 徐海亮 杨泽西 孙燕川 宋建民[1] 卢瑞琪[1] 李丽杰[1] 顾振解 GUO Chang;XU Hailiang;YANG Zexi;SUN Yanchuan;SONG Jianmin;LU Ruiqi;LI Lijie;GU Zhenjie(First Central Hospital of Baoding,Baoding 071000,China;不详)

机构地区：[1]河北省保定市第一中心医院,河北保定071000

出　　处：《中国医学创新》2020年第35期36-39,共4页Medical Innovation of China

基　　金：河北省保定市科技计划项目(1951ZF061)。

摘　　要：目的:探讨常规抗感染治疗下配合胸腔内注入尿激酶治疗脓胸的临床效果。方法:选取2015年10月-2019年10月本院收治的100例脓胸患者为研究对象,根据治疗方法不同将其分为对照组与观察组,各50例。对照组采用常规抗感染治疗,观察组在对照组基础上联合胸腔内注入尿激酶治疗。对比两组临床疗效、恢复情况、胸膜厚度变化情况、胸水黏蛋白及有核细胞数变化情况。结果:观察组的总有效率为96.00%,高于对照组的76.00%,差异有统计学意义(P<0.05)。观察组每日胸水引流量多于对照组,引流管拔管时间、胸腔引流液从黏稠变澄清的时间及脓腔闭合时间均短于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组胸膜厚度低于对照组,差异有统计学意义(P<0.05)。治疗后,两组胸水黏蛋白及有核细胞数与治疗前比较均降低,且观察组胸水黏蛋白及有核细胞数均低于对照组,差异均有统计学意义(P<0.05)。结论:针对脓胸患者,在常规抗感染治疗下配合胸腔内注入尿激酶治疗,效果显著,增加患者每日胸水引流量,使得胸腔内积液得到充分引流,缩短患者引流管拔管时间、胸腔引流液从黏稠变澄清的时间及脓腔闭合时间,减轻了胸膜增厚,具有较高的临床应用价值。Objective:To investigate the clinical effect of conventional anti-infective therapy combined with intrathoracic injection of Urokinase on empyema.Method:A total of 100 patients with empyema admitted to our hospital from October 2015 to October 2019 were selected as the research objects,according to different treatment methods,the patients were divided into the control group and the observation group,50 patients in each group.The control group was treated with routine anti-infection therapy,the observation group was treated with combined Urokinase in the chest,on the basis of the control group.The clinical efficacy,recovery,pleural thickness,pleural mucin and nucleated cell number of the two groups were compared.Result:The total effective rate of the observation group was 96.00%,higher than 76.00%in the control group,the difference was statistically significant(P<0.05).The daily drainage volume of pleural fluid in the observation group was higher than that in the control group,the time of drainage tube extubation,the time of pleural fluid clearing from thickening and the time of abscess cavity closure were shorter than those in the control group,the differences were statistically significant(P<0.05).After treatment,the pleural thickness of the observation group was lower than that of the control group,the difference was statistically significant(P<0.05).After treatment,the number of pleural mucin and nucleated cells in both groups decreased compared with those before treatment,the number of pleural mucin and nucleated cells in the observation group were lower than those in the control group,the differences were statistically significan(P<0.05).Conclusion:For empyema patients,using conventional anti-infection treatment with intrathoracic injection of Urokinase under treatment play a significant clinical curative effect,increase patients daily drainage volume of pleural fluid,makes the pleural effusion in fully drainage,shorten the patients drainage tube extubation,the time of pleural fluid clearing from thickening

关 键 词：尿激酶 脓胸 抗感染 胸腔闭式引流术 胸膜厚度 

分 类 号：R561.6[医药卫生—呼吸系统]